Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 81

1.

The hallmarks of successful anticancer immunotherapy.

Galluzzi L, Chan TA, Kroemer G, Wolchok JD, López-Soto A.

Sci Transl Med. 2018 Sep 19;10(459). pii: eaat7807. doi: 10.1126/scitranslmed.aat7807. Review.

PMID:
30232229
2.

Immunotherapy for triple-negative breast cancer: Existing challenges and exciting prospects.

Jia H, Truica CI, Wang B, Wang Y, Ren X, Harvey HA, Song J, Yang JM.

Drug Resist Updat. 2017 May;32:1-15. doi: 10.1016/j.drup.2017.07.002. Epub 2017 Aug 19. Review.

PMID:
29145974
3.

Neoantigens Generated by Individual Mutations and Their Role in Cancer Immunity and Immunotherapy.

Efremova M, Finotello F, Rieder D, Trajanoski Z.

Front Immunol. 2017 Nov 28;8:1679. doi: 10.3389/fimmu.2017.01679. eCollection 2017. Review.

4.

Advances in personalized cancer immunotherapy.

Kakimi K, Karasaki T, Matsushita H, Sugie T.

Breast Cancer. 2017 Jan;24(1):16-24. doi: 10.1007/s12282-016-0688-1. Epub 2016 Mar 21. Review.

PMID:
27000871
5.

Immune-priming of the tumor microenvironment by radiotherapy: rationale for combination with immunotherapy to improve anticancer efficacy.

Shahabi V, Postow MA, Tuck D, Wolchok JD.

Am J Clin Oncol. 2015 Feb;38(1):90-7. doi: 10.1097/COC.0b013e3182868ec8. Review.

PMID:
25616204
6.

Natural and therapy-induced immunosurveillance in breast cancer.

Kroemer G, Senovilla L, Galluzzi L, André F, Zitvogel L.

Nat Med. 2015 Oct;21(10):1128-38. doi: 10.1038/nm.3944. Review.

PMID:
26444637
7.

Emerging role of immunotherapy in urothelial carcinoma-Immunobiology/biomarkers.

Sweis RF, Galsky MD.

Urol Oncol. 2016 Dec;34(12):556-565. doi: 10.1016/j.urolonc.2016.10.006. Epub 2016 Nov 9. Review.

8.

Oncology meets immunology: the cancer-immunity cycle.

Chen DS, Mellman I.

Immunity. 2013 Jul 25;39(1):1-10. doi: 10.1016/j.immuni.2013.07.012. Review.

9.

Stereotactic ablative radiotherapy and immunotherapy combinations: turning the future into systemic therapy?

Walshaw RC, Honeychurch J, Illidge TM.

Br J Radiol. 2016 Oct;89(1066):20160472. doi: 10.1259/bjr.20160472. Epub 2016 Sep 14. Review.

10.

Immunopharmacogenomics towards personalized cancer immunotherapy targeting neoantigens.

Kiyotani K, Chan HT, Nakamura Y.

Cancer Sci. 2018 Mar;109(3):542-549. doi: 10.1111/cas.13498. Epub 2018 Feb 14. Review.

11.

Tumor and Host Factors Controlling Antitumor Immunity and Efficacy of Cancer Immunotherapy.

Spranger S, Sivan A, Corrales L, Gajewski TF.

Adv Immunol. 2016;130:75-93. doi: 10.1016/bs.ai.2015.12.003. Epub 2016 Jan 22.

12.

Therapeutic gene modified cell based cancer vaccines.

Kozłowska A, Mackiewicz J, Mackiewicz A.

Gene. 2013 Aug 10;525(2):200-7. doi: 10.1016/j.gene.2013.03.056. Epub 2013 Apr 6. Review.

PMID:
23566846
13.

Electrochemotherapy with bleomycin induces hallmarks of immunogenic cell death in murine colon cancer cells.

Calvet CY, Famin D, André FM, Mir LM.

Oncoimmunology. 2014 Apr 15;3:e28131. eCollection 2014.

14.

Vascular normalizing doses of antiangiogenic treatment reprogram the immunosuppressive tumor microenvironment and enhance immunotherapy.

Huang Y, Yuan J, Righi E, Kamoun WS, Ancukiewicz M, Nezivar J, Santosuosso M, Martin JD, Martin MR, Vianello F, Leblanc P, Munn LL, Huang P, Duda DG, Fukumura D, Jain RK, Poznansky MC.

Proc Natl Acad Sci U S A. 2012 Oct 23;109(43):17561-6. doi: 10.1073/pnas.1215397109. Epub 2012 Oct 8.

15.

Genomic analysis of 63,220 tumors reveals insights into tumor uniqueness and targeted cancer immunotherapy strategies.

Hartmaier RJ, Charo J, Fabrizio D, Goldberg ME, Albacker LA, Pao W, Chmielecki J.

Genome Med. 2017 Feb 24;9(1):16. doi: 10.1186/s13073-017-0408-2.

16.

The Role of Neoantigens in Naturally Occurring and Therapeutically Induced Immune Responses to Cancer.

Ward JP, Gubin MM, Schreiber RD.

Adv Immunol. 2016;130:25-74. doi: 10.1016/bs.ai.2016.01.001. Epub 2016 Feb 10. Review.

17.

Targeting Neoantigens for Personalised Immunotherapy.

Pritchard AL.

BioDrugs. 2018 Apr;32(2):99-109. doi: 10.1007/s40259-018-0267-4. Review.

PMID:
29516371
18.

Role of Immunotherapy in Targeting the Bone Marrow Microenvironment in Multiple Myeloma: An Evolving Therapeutic Strategy.

Chung C.

Pharmacotherapy. 2017 Jan;37(1):129-143. doi: 10.1002/phar.1871. Epub 2017 Jan 6. Review.

PMID:
27870103
19.

Immunotherapeutic properties of chemotherapy.

Fournier C, Rivera Vargas T, Martin T, Melis A, Apetoh L.

Curr Opin Pharmacol. 2017 Aug;35:83-88. doi: 10.1016/j.coph.2017.05.003. Epub 2017 May 24. Review.

PMID:
28551360
20.

Cancer Dormancy: A Regulatory Role for Endogenous Immunity in Establishing and Maintaining the Tumor Dormant State.

Baxevanis CN, Perez SA.

Vaccines (Basel). 2015 Jul 30;3(3):597-619. doi: 10.3390/vaccines3030597. Review.

Supplemental Content

Support Center